Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT06243978 Recruiting - Hypertension Clinical Trials

Effectiveness of a Digital Health Application for Primary Hypertension (Liebria)

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

This clinical trial with 328 patients with primary hypertension aims to investigate the effectiveness of the self-guided digital application liebria for patients with primary hypertension.

NCT ID: NCT06235554 Not yet recruiting - Clinical trials for Essential Hypertension

Feasibility Study Evaluating the Safety and Efficacy of the Renal Stimulation by Direct Wire Pacing, During Renal Denervation Procedure

RNS by DWP
Start date: February 20, 2024
Phase: N/A
Study type: Interventional

The goal of this feasibility study is to evaluate the safety and efficacy of the Renal Stimulation (RNS) by Direct Wire Pacing, during Renal Denervation (RDN) procedure in patient candidate for renal denervation with the ParadiseTM System. The main questions it aims to answer are: - Is the RNS before RDN a straightforward method, allowing quantification of the renal sympathetic traffic? - Does the RNS increase blood pressure (SBP), and is this increase significantly blunted after RDN? - Does the 3-month 24h SBP decrease correlated with the RNS-induced SBP change before RDN? - Can the difference between RNS-induced SBP rise before and after RDN be used as a procedural endpoint for RDN? Participants will be asked for their agreement to conduct an RNS before and after the RDN. No additional experimental procedure will be added to the standard of care.

NCT ID: NCT06226727 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"

Start date: February 14, 2024
Phase: Phase 1
Study type: Interventional

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers

NCT ID: NCT06220773 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

Start date: March 2024
Phase: Phase 3
Study type: Interventional

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

NCT ID: NCT06212648 Completed - Hypertension Clinical Trials

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

SP-CAP-002
Start date: March 25, 2022
Phase: Phase 2
Study type: Interventional

This study purpose is to determine the appropriate combination drug dose by comparing safety and efficacy with placebo, candesartan, and amlodipine monotherapy after 8 weeks of administration of SPC1001 to patients with essential hypertension.

NCT ID: NCT06208072 Recruiting - Obesity Clinical Trials

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Despite the available means of treating primary arterial hypertension, the prevalence of hypertensive patients with inadequately controlled blood pressure levels, remains high. The identification of biomarkers with prognostic and predictive roles seems to play an important role in the management of hypertensive patients. Proteomic analysis studies provide encouraging results in the identification of such biomarkers. The goal of this clinical study is to is to highlight peptides through urinary proteomic analysis of obese hypertensive patients, capable of predicting blood pressure response, following treatment with irbesartan or eplerenone.

NCT ID: NCT06205628 Not yet recruiting - Hypertension Clinical Trials

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in patients with hypertension.

NCT ID: NCT06184269 Completed - Clinical trials for Essential Hypertension

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"

Start date: December 23, 2023
Phase: Phase 1
Study type: Interventional

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers

NCT ID: NCT06174766 Not yet recruiting - Hypertension Clinical Trials

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension

NCT ID: NCT06165250 Recruiting - Clinical trials for Essential Hypertension

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

Start date: April 17, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia